Bradley Canino
Stock Analyst at Guggenheim
(4.16)
# 1,565
Out of 5,088 analysts
292
Total ratings
43.7%
Success rate
8.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Bradley Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTH Faeth Therapeutics | Reiterated: Buy | $70 | $19.20 | +264.58% | 2 | Oct 27, 2026 | |
| DMRA Damora Therapeutics | Reiterated: Buy | $40 → $60 | $21.61 | +177.65% | 6 | Sep 24, 2026 | |
| KYMR Kymera Therapeutics | Rated: Buy | $135 → $170 | $122.51 | +38.76% | 22 | Aug 30, 2026 | |
| CELC Celcuity | Rated: Buy | $165 → $175 | $69.46 | +151.94% | 16 | Aug 16, 2026 | |
| JANX Janux Therapeutics | Rated: Buy | $58 → $55 | $18.05 | +204.71% | 10 | Aug 6, 2026 | |
| ORIC ORIC Pharmaceuticals | Reiterated: Buy | $18 | $9.30 | +93.55% | 11 | Aug 3, 2026 | |
| SMMT Summit Therapeutics | Rated: Buy | $40 → $38 | $15.77 | +140.96% | 16 | Jul 23, 2026 | |
| ANTX AN2 Therapeutics | Initiated Coverage: Buy | $9 | $4.52 | +99.12% | 1 | Jul 19, 2026 | |
| SNDX Syndax Pharmaceuticals | Reiterated: Buy | $31 | $14.32 | +116.48% | 18 | Jul 14, 2026 | |
| OLMA Olema Pharmaceuticals | Reiterated: Buy | $38 → $35 | $7.49 | +367.29% | 5 | Jun 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $42 | $9.76 | +330.33% | 2 | May 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $22 → $26 | $19.69 | +32.05% | 18 | May 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 | $13.50 | +159.26% | 3 | Apr 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $54 | $21.75 | +148.28% | 1 | Apr 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $15.56 | +92.80% | 7 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $90 | $63.96 | +40.71% | 3 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 → $7 | $3.40 | +106.19% | 20 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1.83 | - | 17 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $10.72 | n/a | 21 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $10 → $5 | $1.98 | n/a | 5 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $2.06 | n/a | 23 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $3 → $1.5 | $1.18 | n/a | 20 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $63 → $51 | $7.60 | n/a | 25 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.001 | n/a | 13 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $30 | $4.20 | n/a | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $37 | $2.47 | n/a | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $15 | $14.59 | n/a | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $65 | $43.25 | n/a | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $30 | $66.28 | n/a | 1 | Mar 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $55 | $28.90 | n/a | 1 | Mar 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $38 | $20.57 | n/a | 1 | Jul 8, 2020 |
Faeth Therapeutics
Oct 27, 2026
Reiterated: Buy
Price Target: $70
Current: $19.20
Upside: +264.58%
Damora Therapeutics
Sep 24, 2026
Reiterated: Buy
Price Target: $40 → $60
Current: $21.61
Upside: +177.65%
Kymera Therapeutics
Aug 30, 2026
Rated: Buy
Price Target: $135 → $170
Current: $122.51
Upside: +38.76%
Celcuity
Aug 16, 2026
Rated: Buy
Price Target: $165 → $175
Current: $69.46
Upside: +151.94%
Janux Therapeutics
Aug 6, 2026
Rated: Buy
Price Target: $58 → $55
Current: $18.05
Upside: +204.71%
ORIC Pharmaceuticals
Aug 3, 2026
Reiterated: Buy
Price Target: $18
Current: $9.30
Upside: +93.55%
Summit Therapeutics
Jul 23, 2026
Rated: Buy
Price Target: $40 → $38
Current: $15.77
Upside: +140.96%
AN2 Therapeutics
Jul 19, 2026
Initiated Coverage: Buy
Price Target: $9
Current: $4.52
Upside: +99.12%
Syndax Pharmaceuticals
Jul 14, 2026
Reiterated: Buy
Price Target: $31
Current: $14.32
Upside: +116.48%
Olema Pharmaceuticals
Jun 1, 2026
Reiterated: Buy
Price Target: $38 → $35
Current: $7.49
Upside: +367.29%
May 26, 2026
Reiterated: Buy
Price Target: $42
Current: $9.76
Upside: +330.33%
May 25, 2026
Reiterated: Buy
Price Target: $22 → $26
Current: $19.69
Upside: +32.05%
Apr 29, 2026
Reiterated: Buy
Price Target: $35
Current: $13.50
Upside: +159.26%
Apr 15, 2026
Initiated Coverage: Buy
Price Target: $54
Current: $21.75
Upside: +148.28%
Mar 10, 2026
Reiterated: Buy
Price Target: $30
Current: $15.56
Upside: +92.80%
Feb 27, 2026
Reiterated: Buy
Price Target: $90
Current: $63.96
Upside: +40.71%
Feb 26, 2026
Reiterated: Buy
Price Target: $8 → $7
Current: $3.40
Upside: +106.19%
Dec 3, 2025
Downgraded: Hold
Price Target: n/a
Current: $1.83
Upside: -
Sep 3, 2025
Initiated Coverage: Hold
Price Target: n/a
Current: $10.72
Upside: n/a
Sep 3, 2025
Initiated Coverage: Buy
Price Target: $10 → $5
Current: $1.98
Upside: n/a
Mar 27, 2025
Reiterated: Buy
Price Target: $9
Current: $2.06
Upside: n/a
Mar 7, 2025
Reiterated: Hold
Price Target: $3 → $1.5
Current: $1.18
Upside: n/a
Feb 12, 2025
Reiterated: Buy
Price Target: $63 → $51
Current: $7.60
Upside: n/a
Jan 9, 2025
Rated: Hold
Price Target: n/a
Current: $0.001
Upside: n/a
Apr 26, 2021
Initiated Coverage: Buy
Price Target: $30
Current: $4.20
Upside: n/a
Apr 26, 2021
Initiated Coverage: Buy
Price Target: $37
Current: $2.47
Upside: n/a
Apr 26, 2021
Initiated Coverage: Buy
Price Target: $15
Current: $14.59
Upside: n/a
Apr 26, 2021
Initiated Coverage: Buy
Price Target: $65
Current: $43.25
Upside: n/a
Mar 30, 2021
Initiated Coverage: Buy
Price Target: $30
Current: $66.28
Upside: n/a
Mar 30, 2021
Initiated Coverage: Buy
Price Target: $55
Current: $28.90
Upside: n/a
Jul 8, 2020
Initiated Coverage: Buy
Price Target: $38
Current: $20.57
Upside: n/a